NASDAQ:RGEN Repligen (RGEN) Stock Price, News & Analysis $113.52 +1.42 (+1.27%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$113.53 +0.01 (+0.01%) As of 08/7/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Repligen Stock (NASDAQ:RGEN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Repligen alerts:Sign Up Key Stats Today's Range$111.36▼$113.5850-Day Range$112.10▼$134.0052-Week Range$102.96▼$182.52Volume832,018 shsAverage Volume1.04 million shsMarket Capitalization$6.38 billionP/E RatioN/ADividend YieldN/APrice Target$169.45Consensus RatingModerate Buy Company Overview Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts. Read More Repligen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks95th Percentile Overall ScoreRGEN MarketRank™: Repligen scored higher than 95% of companies evaluated by MarketBeat, and ranked 53rd out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingRepligen has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageRepligen has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Repligen's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth37.21% Earnings GrowthEarnings for Repligen are expected to grow by 37.21% in the coming year, from $1.72 to $2.36 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Repligen is -454.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Repligen is -454.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioRepligen has a PEG Ratio of 2.06. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRepligen has a P/B Ratio of 3.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.40% of the float of Repligen has been sold short.Short Interest Ratio / Days to CoverRepligen has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Repligen has recently decreased by 9.81%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRepligen does not currently pay a dividend.Dividend GrowthRepligen does not have a long track record of dividend growth. Sustainability and ESG4.5 / 5Environmental Score-1.33 Percentage of Shares Shorted6.40% of the float of Repligen has been sold short.Short Interest Ratio / Days to CoverRepligen has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Repligen has recently decreased by 9.81%, indicating that investor sentiment is improving significantly. News and Social Media2.6 / 5News Sentiment0.75 News SentimentRepligen has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Repligen this week, compared to 10 articles on an average week.Search InterestOnly 2 people have searched for RGEN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Repligen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.20% of the stock of Repligen is held by insiders.Percentage Held by Institutions97.64% of the stock of Repligen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Repligen's insider trading history. Receive RGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter. Email Address RGEN Stock News Headlines1 Safe-and-Steady Stock on Our Buy List and 2 We Turn DownAugust 7 at 8:33 AM | msn.comWhat is Leerink Partnrs' Forecast for Repligen Q3 Earnings?August 2, 2025 | americanbankingnews.comMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI. | Brownstone Research (Ad)FY2025 EPS Estimates for Repligen Lifted by William BlairAugust 1, 2025 | americanbankingnews.comRepligen Stock Outlook: Risk Skewed To The Downside Through 2026July 31, 2025 | benzinga.comRepligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing DigitalizationJuly 31, 2025 | globenewswire.comRepligen Corporation (NASDAQ:RGEN) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJuly 31, 2025 | americanbankingnews.comWhy Repligen (RGEN) Stock Is Up TodayJuly 30, 2025 | msn.comSee More Headlines RGEN Stock Analysis - Frequently Asked Questions How have RGEN shares performed this year? Repligen's stock was trading at $143.94 at the start of the year. Since then, RGEN shares have decreased by 21.1% and is now trading at $113.52. How were Repligen's earnings last quarter? Repligen Corporation (NASDAQ:RGEN) announced its quarterly earnings results on Tuesday, July, 29th. The biotechnology company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.40 by $0.03. The company's revenue for the quarter was up 14.8% on a year-over-year basis. Read the conference call transcript. Does Repligen have any subsidiaries? The following companies are subsidiaries of Repligen: ARTeSYN Biosolutions Holdings Ireland Limite, Non-Metallic Solutions Inc, Engineered Molding Technology LLC, C Technologies Inc., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, and more. Who are Repligen's major shareholders? Top institutional shareholders of Repligen include Conestoga Capital Advisors LLC (1.74%), Stephens Investment Management Group LLC (0.93%), Geneva Capital Management LLC (0.87%) and Riverbridge Partners LLC (0.66%). Insiders that own company stock include Anthony Hunt, Karen A Dawes, Jon Snodgres, Christine Gebski, Ralf Kuriyel, James Bylund, Martin D Madaus and Margaret Pax. View institutional ownership trends. How do I buy shares of Repligen? Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Repligen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Repligen investors own include NVIDIA (NVDA), Humana (HUM), Meta Platforms (META), Salesforce (CRM), CrowdStrike (CRWD), Broadcom (AVGO) and Advanced Micro Devices (AMD). Company Calendar Last Earnings7/29/2025Today8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:RGEN CIK730272 Webwww.repligen.com Phone(781) 250-0111Fax781-250-0115Employees1,778Year Founded1981Price Target and Rating Average Price Target for Repligen$169.45 High Price Target$204.00 Low Price Target$130.00 Potential Upside/Downside+49.3%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($0.25) Trailing P/E RatioN/A Forward P/E Ratio66.00 P/E Growth2.06Net Income-$25.51 million Net Margins-2.05% Pretax Margin-2.02% Return on Equity4.65% Return on Assets3.26% Debt Debt-to-Equity Ratio0.27 Current Ratio6.79 Quick Ratio5.79 Sales & Book Value Annual Sales$634.44 million Price / Sales10.05 Cash Flow$3.15 per share Price / Cash Flow36.08 Book Value$35.21 per share Price / Book3.22Miscellaneous Outstanding Shares56,180,000Free Float55,509,000Market Cap$6.38 billion OptionableOptionable Beta1.05 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:RGEN) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repligen Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Repligen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.